The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Oncologic outcomes following biologic therapy for immune-related cutaneous adverse events.
 
Tara Maier
No Relationships to Disclose
 
Alina Markova
Consulting or Advisory Role - AstraZeneca; Genzyme; Incyte; Treeline Biosciences
Research Funding - Amryt Pharma; Incyte; Janssen; Kintara Therapeutics; NIH U01; NIH U54; NIH/NCI
Patents, Royalties, Other Intellectual Property - UpToDate
Travel, Accommodations, Expenses - Incyte
 
Stephen Dusza
No Relationships to Disclose
 
Elena Goleva
No Relationships to Disclose
 
Donald Leung
Honoraria - Sanofi
Consulting or Advisory Role - Sanofi
Research Funding - Genentech; Sanofi
Travel, Accommodations, Expenses - Sanofi
 
Jeffrey Kern
Consulting or Advisory Role - Lahjavida
 
Allison Gordon
Consulting or Advisory Role - Association of Cancer Care Centers; Pyxis; Xencor
 
Fazilat Khwaja
No Relationships to Disclose
 
Michael Postow
Consulting or Advisory Role - Bristol-Myers Squibb; Cancer Expert Now; Chugai Pharma; Eisai; Erasca, Inc; Intellisphere; Lyvgen Biopharma; Merck; MJH Associates; Nektar; Novartis; Pfizer; Replimune; WebMD
Research Funding - Array BioPharma (Inst); BioAtla (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); ImaginAb (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst)
Patents, Royalties, Other Intellectual Property - I am a contributor to www.uptodate.com and receive royalties.
 
Jonathan Rosenberg
Honoraria - Astellas Pharma; Merck
Consulting or Advisory Role - Aktis Oncology; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Domain Therapeutics; EMD Serono; Generate Biomedicines; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Mirati Therapeutics; Pfizer; Roche/Genentech; Samsung Bioepis; Seagen; Summit Therapeutics; Tyra Biosciences
Research Funding - Acrivon Therapeutics; Astellas Pharma (Inst); Bristol-Myers Squibb; Lilly; Pfizer
Patents, Royalties, Other Intellectual Property - Amplification of chromosome 1q23 to predict cancer outcomes (Inst); Predictor of platinum sensitivity (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
(OPTIONAL) Uncompensated Relationships - Alliance for Clinical Trials in Oncology; Kalivir Immunotherapeutics
 
Mario Lacouture
Stock and Other Ownership Interests - Oncoderm (I)
Honoraria - Apricity Health; AstraZeneca; Deciphera; Hoth Therapeutics; Incyte; Innovaderm; Janssen; Kinnate Biopharma; Kintara Therapeutics; L'Oreal; La Roche-Posay; Loxo; Lutris; MJH Associates; NanOlogy; Novartis; Novocure; OnQuality Pharmaceuticals; RBC consultants; Relay Therapeutics; Repare Therapeutics; Roche/Genentech; Seagen; Seattle Genetics/Astellas; Trifecta; Tyra Biosciences
Consulting or Advisory Role - Apricity Health; AstraZeneca; Deciphera; Genentech; Incyte; Innovaderm; Janssen Research & Development; Kinnate Biopharma; Kintara Therapeutics; La Roche-Posay; Loxo; Lutris; Novartis; Novocure; OnQuality Pharmaceuticals; Relay Therapeutics; Repare Therapeutics; Roche; Seagen; Tyra Biosciences
Research Funding - AstraZeneca/MedImmune; Columbia University; Lutris (Inst); National Jewish Health; Novartis; Novocure (Inst); OnQuality Pharmaceuticals; OnQuality Pharmaceuticals (Inst); Paxman
Other Relationship - Oncoderm (I)
(OPTIONAL) Uncompensated Relationships - Oncoderm
 
Neil Shah
Honoraria - MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb/Medarex; Merck Sharp & Dohme Corp.; Pfizer
Research Funding - Aravive (Inst); Exelixis (Inst); HiberCell (Inst)
Travel, Accommodations, Expenses - Merck